How to comply with the regulatory requirements for manufacturing custom-made medical devices.
Similar Posts
Guidance: Strengthening supply chain cyber security at the MHRA
MHRA invites current and former suppliers to join Risk Ledger and complete a security profile to strengthen supply chain cyber security.
UK sets out world‑leading pathway for space‑manufactured drugs
Patients could benefit from more effective, higher quality and longer lasting medicines as the UK sets out a clearer route to bring drugs manufactured in space safely to market.
Electronic Common Technical Document (eCTD) submissions update
Since, April 2024, the MHRA has been using Lorenz DocuBridge for eCTD management in product license submissions. This change is part of the modernisation of the MHRA’s Legacy Systems and is one of the initial tools launched in the RegulatoryConnect programme.
Borderline products: how to tell if your product is a medicine
How the MHRA makes decisions on what is a medicinal product (borderline products).
Improving Information Supplied with Gabapentinoids (Pregabalin/Gabapentin), Benzodiazepines and Z-Drugs
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and
tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks.Guidance: Get more help to apply for medicines Integrated Scientific Advice (ISA)
Extra information for the Medicines and Healthcare products Regulatory Agency (MHRA) and National Institute for Health and Care Excellence (NICE) Integrated Scientific Advice (ISA) service.